Publication Information (EuropePMC) | |
Title | Genetic variants in glutamate-, Aβ-, and tau-related pathways determine polygenic risk for Alzheimer's disease. |
PubMed ID | 33303219(Europe PMC) |
doi | 10.1016/j.neurobiolaging.2020.11.009 |
Publication Date | Nov. 12, 2020 |
Journal | Neurobiol Aging |
Author(s) | Lawingco T, Chaudhury S, Brookes KJ, Guetta-Baranes T, Guerreiro R, Bras J, Hardy J, Francis P, Thomas A, Belbin O, Morgan K. |
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS004918 (PRS8_Synapse) |
PGP000649 | Lawingco T et al. Neurobiol Aging (2020) |
Late-onset Alzheimers disease (based on SNPs in genes involved in synaptic function) | late-onset Alzheimer's disease | 8 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004918/ScoringFiles/PGS004918.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM021384 | PGS004918 (PRS8_Synapse) |
PSS011719| European Ancestry| 136 individuals |
PGP000649 | Lawingco T et al. Neurobiol Aging (2020) |
Reported Trait: Late-onset Alzheimer's disease | — | AUROC: 0.731 | — | — | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS011719 | Samples used in this study were extracted from autopsied brain tissue. Samples were taken from cognitively normal individuals witth a dementia rating of 0 (controls) and from late-onset Alzheimer's disease (LOAD) patients who had a clinical diagnosis of dementia due to AD and neuropathological confirmation of AD. | — | [ ,
39.0 % Male samples |
— | European | — | BfDR | — |